# The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

> **NCT03601871** · NA · UNKNOWN · sponsor: **Yunpeng Liu** · enrollment: 880 (estimated)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone
- **DRUG:** 5-HT3 antagonists

## Key facts

- **NCT ID:** NCT03601871
- **Lead sponsor:** Yunpeng Liu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-12
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601871, "The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03601871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*